Saniona AB (SANION) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Saniona AB (SANION) has a cash flow conversion efficiency ratio of -0.125x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-79.51 Million ≈ $-8.56 Million USD) by net assets (Skr635.16 Million ≈ $68.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Saniona AB stock valuation for the company's overall valuation and market capitalisation.
Saniona AB - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Saniona AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Saniona AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Saniona AB ranked by their cash flow conversion efficiency. Explore earnings quality score of Saniona AB to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dexxos Participações S.A
SA:DEXP3
|
0.115x |
|
Theratechnologies Inc.
TO:TH
|
-0.095x |
|
Silver X Mining Corp
V:AGX
|
0.051x |
|
Waterco Ltd
AU:WAT
|
0.044x |
|
PHA Co. Ltd
KQ:043370
|
0.033x |
|
Eastern Communications Co Ltd B
SHG:900941
|
0.030x |
|
Mercuries Data Systems Ltd
TW:2427
|
0.301x |
|
Kolmar BNH Co. Ltd
KQ:200130
|
0.049x |
Annual Cash Flow Conversion Efficiency for Saniona AB (2013–2025)
The table below shows the annual cash flow conversion efficiency of Saniona AB from 2013 to 2025. View Saniona AB stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr635.16 Million ≈ $68.35 Million |
Skr273.86 Million ≈ $29.47 Million |
0.431x | -59.89% |
| 2024-12-31 | Skr231.82 Million ≈ $24.95 Million |
Skr249.20 Million ≈ $26.82 Million |
1.075x | -72.43% |
| 2023-12-31 | Skr-21.94 Million ≈ $-2.36 Million |
Skr-85.53 Million ≈ $-9.20 Million |
3.898x | +172.98% |
| 2022-12-31 | Skr52.71 Million ≈ $5.67 Million |
Skr-281.54 Million ≈ $-30.30 Million |
-5.341x | -336.56% |
| 2021-12-31 | Skr282.00 Million ≈ $30.35 Million |
Skr-345.04 Million ≈ $-37.13 Million |
-1.224x | -322.61% |
| 2020-12-31 | Skr603.46 Million ≈ $64.94 Million |
Skr-174.71 Million ≈ $-18.80 Million |
-0.290x | +82.82% |
| 2019-12-31 | Skr58.44 Million ≈ $6.29 Million |
Skr-98.47 Million ≈ $-10.60 Million |
-1.685x | -190.08% |
| 2018-12-31 | Skr39.46 Million ≈ $4.25 Million |
Skr-22.92 Million ≈ $-2.47 Million |
-0.581x | +61.88% |
| 2017-12-31 | Skr37.63 Million ≈ $4.05 Million |
Skr-57.34 Million ≈ $-6.17 Million |
-1.524x | -1139.50% |
| 2016-12-31 | Skr54.25 Million ≈ $5.84 Million |
Skr7.95 Million ≈ $855.87K |
0.147x | +126.93% |
| 2015-12-31 | Skr52.94 Million ≈ $5.70 Million |
Skr-28.82 Million ≈ $-3.10 Million |
-0.544x | +39.93% |
| 2014-12-31 | Skr8.78 Million ≈ $944.98K |
Skr-7.96 Million ≈ $-856.41K |
-0.906x | +86.10% |
| 2013-12-31 | Skr575.00K ≈ $61.88K |
Skr-3.75 Million ≈ $-403.34K |
-6.518x | -- |
About Saniona AB
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more